Tranexamic Acid for Urethral Stricture

(REDUCER Trial)

This trial tests whether tranexamic acid (TXA), a medication that reduces bleeding, can lower blood loss during urethroplasty surgery. Urethroplasty repairs urethral stricture, a condition where the urethra narrows. Participants will either receive TXA during surgery or undergo the standard procedure without it. The study aims to determine if TXA can maintain hemoglobin levels and reduce complications. Individuals undergoing urethroplasty for urethral stricture who can provide informed consent might be suitable for this trial. As a Phase 4 trial, this research focuses on understanding how an already FDA-approved and effective treatment can benefit more patients.

The trial does not specify if you need to stop taking your current medications, but if you are on anticoagulants (blood thinners), you may need to stop them if they can't be safely held during the surgery period.

Research has shown that tranexamic acid (TXA) is generally safe and well-tolerated in various surgeries. One study found that using TXA during prostate surgeries controlled blood loss without causing harmful side effects. Another study demonstrated that TXA reduced blood loss and maintained stable hemoglobin levels during these surgeries.

Researchers are excited about tranexamic acid (TXA) for urethral stricture because it offers a new approach by potentially reducing bleeding during urethroplasty surgery, which is not something standard options like simple urethroplasty or dilation typically address. TXA works by stabilizing blood clots, which can lead to less blood loss and potentially quicker recovery times post-surgery. Unlike standard surgical treatments that focus on physically correcting the stricture, TXA adds a biochemical edge by targeting blood clotting processes, making it an innovative addition to surgical care.

This trial will compare tranexamic acid (TXA) with standard surgical care in participants undergoing urethroplasty. Studies have shown that TXA reduces blood loss during surgery. Research indicates that TXA can lower the risk of major bleeding by 3.4% in surgeries involving the urinary system. It also reduces the need for blood transfusions and improves surgical outcomes without increasing the risk of blood clots. A review of studies found that TXA helps control blood loss and maintains stable hemoglobin levels, which is crucial for healthy blood after surgery. Overall, TXA is considered effective for reducing bleeding during surgeries like urethroplasty.¹²⁶⁷⁸